Systems biology-guided identification of synthetic lethal gene pairs and its potential use to discover antibiotic combinations by Aziz, Ramy K. et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 21, 2017
Systems biology-guided identification of synthetic lethal gene pairs and its potential
use to discover antibiotic combinations
Aziz, Ramy K.; Monk, Jonathan M.; Lewis, R. M.; Loh, Suh I.; Mishra, A.; Nagle, A. A.; Satyanarayana, C.;
Dhakshinamoorthy, S.; Luche, M.; Kitchen, D. B.; Andrews, K. A.; Fong, N. L.; Li, H. J.; Palsson, B. O.;
Charusanti, Pep
Published in:
Scientific Reports
Link to article, DOI:
10.1038/srep16025
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Aziz, R. K., Monk, J. M., Lewis, R. M., Loh, S. I., Mishra, A., Nagle, A. A., ... Charusanti, P. (2015). Systems
biology-guided identification of synthetic lethal gene pairs and its potential use to discover antibiotic
combinations. Scientific Reports, 5, [16025]. DOI: 10.1038/srep16025
1Scientific RepoRts | 5:16025 | DOi: 10.1038/srep16025
www.nature.com/scientificreports
Systems biology-guided 
identification of synthetic lethal 
gene pairs and its potential use to 
discover antibiotic combinations
Ramy K. Aziz1,2, Jonathan M. Monk2, Robert M. Lewis3, Suh In Loh4, Arti Mishra4, 
Amrita Abhay Nagle4, Chitkala Satyanarayana4, Saravanakumar Dhakshinamoorthy4, 
Michele Luche3, Douglas B. Kitchen3, Kathleen A. Andrews2, Nicole L. Fong2, Howard J. Li2, 
Bernhard O. Palsson2 & Pep Charusanti2,5
Mathematical models of metabolism from bacterial systems biology have proven their utility across 
multiple fields, for example metabolic engineering, growth phenotype simulation, and biological 
discovery. The usefulness of the models stems from their ability to compute a link between 
genotype and phenotype, but their ability to accurately simulate gene-gene interactions has not 
been investigated extensively. Here we assess how accurately a metabolic model for Escherichia coli 
computes one particular type of gene-gene interaction, synthetic lethality, and find that the accuracy 
rate is between 25% and 43%. The most common failure modes were incorrect computation of 
single gene essentiality and biological information that was missing from the model. Moreover, we 
performed virtual and biological screening against several synthetic lethal pairs to explore whether 
two-compound formulations could be found that inhibit the growth of Gram-negative bacteria. One 
set of molecules was identified that, depending on the concentrations, inhibits E. coli and S. enterica 
serovar Typhimurium in an additive or antagonistic manner. These findings pinpoint specific ways in 
which to improve the predictive ability of metabolic models, and highlight one potential application 
of systems biology to drug discovery and translational medicine.
Genome-scale metabolic network reconstructions form a cornerstone of microbial systems biology as 
they capture in one framework all known genes, proteins, and reactions within the metabolic network 
of an organism1,2. The subsequent conversion of a reconstruction into a mathematical model suitable 
for numerical computation allows one to compute cellular phenotypes for different growth conditions. 
In this way, metabolic reconstructions and their associated models constitute a computational platform 
that can be used to investigate the link between genotype and phenotype. This property distinguishes 
a metabolic model from static maps of biochemical pathways. The latter is a catalog of all known path-
ways in a network, whereas the former provides additional information such as growth rates in different 
environments; substrate uptake and product secretion rates; and the identity of pathways that are likely 
to be active for a given growth condition versus pathways that are present but not utilized. Such models 
have found use in metabolic engineering3,4, network analysis5,6, and have driven biological discovery7,8.
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For well-characterized organisms such as Escherichia coli, Bacillus subtilis, and Saccharomyces cerevi-
siae, metabolic models simulate single gene essentiality with overall accuracy of approximately 90%9–12. 
This rate drops to 49%, however, when the S. cerevisiae iLL672 metabolic model is used to compute 
synthetic lethality instead13. Although this rate is two orders of magnitude better than if two genes 
are selected by random chance13, it still represents a drop-off when compared to the ~90% accuracy 
rate for single gene essentiality. The simulation accuracy of synthetically lethal (SL) gene pairs for the 
E. coli metabolic model10 is not known since it is much more difficult to create large numbers of double 
deletion mutants in E. coli than it is in S. cerevisiae. Correct simulation of synthetic lethality, and more 
generally gene-gene interactions, therefore constitutes one area in which metabolic models can be greatly 
improved.
With greater biological accuracy, the in silico computation of synthetic lethal gene pairs could become 
one strategy to rationally discover combination therapeutics. Currently, some common strategies to dis-
cover drug combinations include: the inhibition of multiple key steps in pathways known to be essential, 
such as folate biosynthesis14,15; the inhibition of an essential enzyme and another protein known to confer 
resistance, as is the case with Augmentin16; and high-throughput screening of a compound library in 
the presence of a second compound17,18. The inhibition of synthetic lethal proteins has been applied to 
the field of cancer therapeutics19,20, most notably the inhibition of poly(adenosine diphosphate [ADP]–
ribose) polymerases (PARPs) in different cancers21–23. Specifically, PARPs and BRCA1/BRCA2 form a 
synthetic lethal pair in cancer cells, but in some cases the latter has developed a loss-of-function muta-
tion such that only one compound targeting the PARPs needed to be developed. The situation would 
differ for antibiotics: two compounds targeting both members of the SL pair would likely be needed. 
This strategy becomes more attractive if the two molecules act synergistically, since synergy can result 
in lower individual dosages of the two compounds and possibly more target specificity24. Metabolic 
models can significantly accelerate the search for SL gene pairs. To take Escherichia coli K12 MG1655 as 
an example, a strategy based on the inhibition of two different enzymes would yield a total search space 
of approximately 8 million protein pairs since this strain has 4140 annotated coding DNA sequences 
(CDSs). In practice, however, the search for potential targets within this space is more focused, and 
metabolic models can narrow the search space even further due to their ability to simulate the effect of 
gene knockouts on growth.
We analyze here how accurately the most current version of the E. coli metabolic model10 computes 
synthetic lethality, and identify the most common failure modes to pinpoint specific areas in which the 
model can be improved. Furthermore, we perform virtual screening against a subset of validated SL pairs 
as a first step to find potential inhibitors, and then screen the most promising compounds both as single 
agents and in combination to assess the feasibility with which combinations of inhibitors can be found 
against the SL proteins. In the combination studies, we also assess whether the inhibitors exhibit synergy, 
additivity, or antagonism, and examine whether these effects match the expected outcome based on their 
protein targets and simulation data.
Results
Metabolic network models can guide the identification of synthetic lethal gene pairs. We 
used metabolic network models for E. coli EDL93325, K. pneumoniae MGH7857826, Y. pestis CO9227, and 
Salmonella enterica serovar Typhimurium LT228 (hereafter referred to as S. Typhimurium) to guide our 
search for possible synthetic lethal pairs in these organisms. Other model-driven studies of synthetic 
lethality in E. coli have used metabolic models of the non-pathogenic K12 MG1655 strain29,30; however, 
we used a model for strain EDL933 to allow for potential application to infectious disease and drug dis-
covery (Fig. 1). This strain is a prototypical one for the enterohemorrhagic O157:H7 serotype that has 
caused multiple outbreaks of food poisoning in the United States31. The strains chosen to represent the 
three other bacteria are likewise pathogenic variants for those organisms.
In LB media, simulations of the four models resulted in 65 (E. coli), 76 (K. pneumoniae), 78 (Y. pestis), 
and 51 (S. Typhimurium) computed SL pairs. Of these, three pairs are shared among all four models: 
asnA/asnB (amino acid metabolism), cmk/pyrH (nucleotide salvage pathway), and tdk/thyA (nucleotide 
salvage pathway). After these three pairs are removed, eight, five, three, and zero pairs are shared among 
three of the four models, respectively. These pairs fall predominantly into the following classifications: 
folate metabolism, amino acid metabolism (asparagine, methionine, and aromatic amino acids via the 
shikimate pathway), cofactor biosynthesis (pantothenate), and TCA cycle. These 19 SL gene pairs cor-
respond to 13 unique reaction pairs, while there were six cases in which two or more SL gene pairs 
catalyzed the same reaction in the models. For example, lpdA/sucC and lpdA/sucD are two distinct SL 
gene pairs, but they correspond to only one SL reaction pair since SucC and SucD form a heterodimer. 
These data are summarized in Fig. 2.
In defined media, the number of computed SL pairs was 69 (E. coli), 70 (K. pneumoniae), 73 (Y. pes-
tis), and 87 (S. Typhimurium). The defined medium for Y. pestis was BCS media32, while the recipe for 
glucose M9 was used as the defined medium for the other three organisms. Five pairs were shared among 
all four models, asnA/asnB and cmk/pyrH as in LB medium plus glyA/serA, glyA/serB, and purN/purT. 
Unlike in LB, simulations did not identify tdk/thyA as a putative SL pair in defined media because thyA 
is singly essential under these conditions. Besides these five pairs, 21 other SL gene pairs were present 
in at least three of the four models. They again belong predominantly to folate metabolism, amino acid 
www.nature.com/scientificreports/
3Scientific RepoRts | 5:16025 | DOi: 10.1038/srep16025
metabolism, and TCA cycle, with several additional pairs from ion transport and the pentose phosphate 
pathway. Overall, the 26 SL gene pairs correspond to 16 unique SL reaction pairs. These data are like-
wise summarized in Fig. 2. The full list of SL gene pairs for both LB and defined media can be found in 
Supplementary Dataset 1.
Figure 1. Five-step workflow for the model-guided identification of compounds that inhibit synthetic 
lethal protein pairs. The use of mathematical models in step 1 narrows the search space for SL pairs, after 
which the pairs are validated experimentally and then subjected to virtual and biological screening.
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The overall accuracy of model-guided prediction of synthetic lethality was between 25% and 
43%. We tested how accurately the models could predict synthetic lethality a priori by constructing 
eight double knockout mutants in E. coli EDL933 and four in Salmonella enterica strain 14028s. In 
E. coli, one of the eight double mutants was experimentally synthetically lethal (hemF/hemN), whereas 
in Salmonella it was two out of four (gltB/gdhA and lpdA/sucC) (Table 1). Therefore, the overall accuracy 
was three out of twelve (25%). Five of the false positives resulted from cases in which one of the two 
genes was singly essential, and therefore synthetic lethality is not possible. If these are removed from the 
calculation, the accuracy rate is three out of seven (43%). No proper benchmark of these results exists 
since a systematic, large-scale study that examines the number of SL pairs in E. coli has not been carried 
out yet; however, of 692,865 randomly chosen gene pairs in yeast that were experimentally tested, only 
0.56% displayed a synthetically lethal or sick phenotype13. If a similar ratio holds for E. coli, then the 
models will have outperformed random selection by a statistically significant amount.
Different mechanisms lead to the lethal phenotype in the three identified SL pairs. HemF and HemN 
both catalyze the same essential oxidative decarboxylation step during porphyrin biosynthesis, but HemF 
is active under aerobic conditions while HemN is active under anaerobic conditions. Their removal 
consequently eliminates an essential reaction. GltB and GdhA catalyze parallel reactions within glu-
tamate biosynthesis: the deletion of gltB and gdhA removes all possible routes from 2-oxoglutarate to 
L-glutamate, leading to glutamate auxotrophy. LpdA is a component of two separate complexes that 
catalyze different steps within the TCA cycle, and SucC is the β -subunit of succinyl-CoA synthetase, also 
within the TCA cycle. The deletion of these two genes severely reduces flux through this critical pathway, 
thereby accounting for the SL phenotype.
Incorrect computation of single gene essentiality and missing biological information were 
the two most common causes of inaccurate SL predictions. We analyzed the nine cases in 
which the predicted SL phenotype proved to be inaccurate to determine the underlying cause, since 
such information reveals areas for further improvement of the models. The two most common causes 
were situations in which one of the two genes in the pair turned out to be singly essential, and missing 
biological information that consequently was not represented in the models.
There were five cases in which at least one of the two genes is singly essential (Table 1), but the rea-
sons for the discrepancies with simulation data varied. In one case, the two genes (aroE/ydiB) catalyze 
the same essential reaction in the model, but aroE is singly essential in LB. RNA-seq data indicate that 
Figure 2. The number of SL genes and their corresponding reactions in each of the four individual 
models, and the number that were shared among multiple models. BCS media was the defined medium 
for the Y. pestis model whereas glucose M9 was the defined medium for the other three. Abbreviations: E.c.: 
E. coli EDL933; K.p.: K. pneumoniae MGH78578; Y.p.:Y. pestis CO92; S.T.: S. Typhimurium.
www.nature.com/scientificreports/
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ydiB is not expressed during exponential growth in LB33,34, implying that missing regulatory information 
that is beyond the scope of metabolic models is responsible for this error. Likewise, missing regulatory 
information centered on the glyoxylate shunt underlies the error with mdh/ppc. In contrast, in two cases 
(metL/thrA and fabA/tesB) the non-essential genes (thrA and tesB) are expressed under the growth con-
ditions expected to result in synthetic lethality. This scenario points to incorrect assignment of gene 
function as a likely cause. In the last case (glyA/serA), both genes were singly essential.
There were three cases in which missing biological information led to erroneous simulation results. 
Simulation of a purT/purN double knockout resulted in a model for E. coli that could not synthesize 
Model-predicted 
SL pair Organism
Growth 
medium on 
which synthetic 
lethality was 
predicted to 
occur
Experimentally 
valid SL pair?
Reason for 
incorrect 
prediction
hemF/hemN E. coli LB Yes
gltB/gdhA S. Typhimurium M9 Yes
lpdA/sucC S. Typhimurium M9 Yes
metE/metH E. coli LB No 1
ntpA/mutT E. coli M9 No 4
fabA*/tesB E. coli LB No 3
purT/purN E. coli LB No 4
ydiB/aroE* E. coli LB No 3
metL*/thrA E. coli M9 No 3
cstC/argD E. coli M9 No 4
glyA*/serA* S. Typhimurium M9 No 3
mdh/ppc* S. Typhimurium M9 No 2,3
ntpA/hemF EDL933 Negative control; double mutant was viable on LB as expected
Table 1.  Putative SL gene pairs that were experimentally constructed. Eight and four double mutants 
were constructed in E. coli EDL933 and S. Typhimurium 14028s, respectively, and tested for synthetic 
lethality in the indicated growth medium. The nine pairs that did not show synthetic lethality as predicted 
were classified into one of four classes as follows: 1. Important biological information was not incorporated 
into the metabolic model due to inherent limitations of the model; 2. Missing regulatory information not 
captured by the model; 3. At least one of the two genes appears to be singly essential experimentally, but 
was not singly essential in the model. The singly essential gene is denoted with an asterisk. For the glyA/serA 
pair, both genes are singly essential; 4. Missing biological information, e.g. the possible presence of another 
unidentified homolog.
Target 
Protein
Number of 
Compounds 
Tested
Number of Active Compounds
E. coli S. Typhimurium
IC50 of 
0.1–200 μM
>30% 
inhibition 
at 200 μM
IC50 of 
0.1–200 μM
>30% 
inhibition 
at 200 μM
HemN 89 0 1 0 0
SucC 279 0 5 1 3
LpdA 246 0 0 0 0
GlyA 195 0 0 0 0
SerA 154 2 0 2 1
HemF 84 0 0 0 0
Mdh1 203 0 0 0 0
Ppc1 78 0 4 0 1
Table 2.  Results of antimicrobial screening of 1,328 compounds against E. coli and S. Typhimurium. 
The table shows the number of compounds tested for each of the target proteins and their respective 
confirmed activity profile against the two bacteria using repurchased and reweighed samples.
www.nature.com/scientificreports/
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purine, an essential metabolite; however, the double knockout was viable in LB medium (but not glucose 
M9), an experimental outcome that has been seen previously in other strains of E. coli35. These data sug-
gest the presence of an unidentified purine transporter. In the model, the two proteins MutT and NtpA 
catalyze the same essential reaction within folate biosynthesis, forming the basis for their computed syn-
thetic lethality. The experimental viability of this double mutant strongly suggests that at least one other 
unidentified protein can catalyze the same reaction. Similarly, ArgD and CstC are putative paralogs that 
also catalyze the same essential reaction in the model.
Validated synthetic lethal pairs can guide the search for possible combination therapeu-
tics. We performed virtual and biological screening to identify potential inhibitors against four sets 
of proteins: hemF/hemN, lpdA/sucC, glyA/serA, and mdh/ppc. The first two are synthetic lethal pairs 
(Table  1), and compounds that inhibit them were hypothesized to act synergistically. The latter two 
were screened for use as controls. The glyA/serA pair is a case in which both genes are singly essential 
in S. Typhimurium, so they were anticipated to exhibit additivity instead of synergy. The mdh/ppc pair 
is a case in which one gene (ppc) is singly essential. Consequently, neither synergy nor additivity was 
anticipated for this pair. We followed the following general strategy to identify potential combinations 
of inhibitors: 1) perform virtual screening against the enzyme targets; 2) screen the compounds against 
E. coli and S. Typhimurium to determine their activity as single agents; and 3) screen a subset of the 
compounds in combination according to the SL pairing to evaluate potential synergy, additivity, and 
antagonism. It should be noted that, for true SL pairs, compounds that inhibit either of the two proteins 
are not expected to show strong activity as single agents. Instead, inhibition is expected to be strongest 
when both compounds are present.
We first used molecular docking to identify compounds likely to inhibit the eight proteins in either 
E. coli or S. Typhimurium as single agents. A diverse collection of 300,000 to 600,000 compounds was 
docked to binding sites within each of the eight proteins using a high throughput docking procedure 
(HTVS mode, see Supplementary File 1). High scoring compounds from these searches were used as 
similarity probes against a 70 million compound library and the hits were docked in a higher precision 
mode (SP mode). This step resulted in a set of 1,039 compounds.
The 1,039 compounds were purchased and tested in a 10-point dose response format (top test concen-
tration of 200 μ M and 2-fold dilution) to determine their IC50 and % inhibition against the two bacteria. 
Although virtual screening was carried out against protein targets, this step was performed as a bacterial 
growth inhibition assay in which the readout was cellular growth. Standard compounds were also tested 
along with every batch of compounds screened in the assay for quality control purposes. This step iden-
tified 67 compounds that exhibited over 20% inhibition at any dose.
These 67 weak hits were then used as probes to search for chemically similar structures that might 
also be active, and these compounds were likewise docked against the eight target proteins. This step 
resulted in a group of 289 compounds that were also purchased and screened in the cellular assays. 
Therefore, a total of 1328 compounds were identified by virtual screening and tested in the first round of 
biological screening as potential inhibitors against E. coli and S. Typhimurium (Table 2). After a hit was 
identified against one protein (% inhibition > 20% against either bacterium), it was subsequently docked 
against all eight proteins to assess whether it might bind to the other targets as well. If the docking 
score was at least one standard deviation above the average score for that site, then it was presumed to 
bind that additional site. A third qualitative assignment was made if the scores from two methods were 
deemed significant (see Materials and Methods). These multiple assignments are listed in Table 3 for the 
most active compounds.
Three of the 1328 compounds showed reproducible activity against E. coli, S. Typhimurium, or both 
during individual compound screening with IC50 < 200 μ M and/or percent inhibition over 30% (Table 3), 
and we selected them for combination studies. SERA-126 inhibited the growth of both bacteria. Its 
IC50 value was lower for S. Typhimurium than it was for E. coli. SIM1-074 inhibited the growth of S. 
Typhimurium but did not have significant effect on the growth of E. coli. SIM4-003 inhibited the growth 
of both E. coli and S. Typhimurium with IC50 values of < 50 μ M.
From the docking calculations against all eight proteins, combinations of these three compounds were 
presumed to target three of the four protein pairs (Table  3); however, the calculations suggested that 
SerA/GlyA would be the primary target. SERA-126 and SIM4-003 most likely target SerA and SIM1-074 
is predicted to inhibit GlyA. This pair was not an experimentally valid SL pair because the two genes 
are singly essential (Table 1). Although SIM1-074 targets SucC in the calculations, combinations of these 
three compounds were not predicted to inhibit SucC/LpdA because SERA-126 and SIM4-003 are pre-
dicted to inhibit LpdA only weakly. The compounds exhibited weak inhibition for the HemN/HemF pair 
in the calculations, and it is equally likely that each compound would bind to HemN only. None of the 
compounds bound to Ppc in the calculations; therefore, the compounds were not predicted to have an 
effect on the Mdh/Ppc pair.
Two concentrations of SIM1-074 were tested against two concentrations each of SERA-126 and SIM4-
003 against both E. coli and S. Typhimurium. The chemical similarity between SERA-126 and SIM4-
003 suggested that these compounds would share a similar mechanism of action, and therefore they 
were not tested in combination with each other. The tested combinations were assigned to have either a 
www.nature.com/scientificreports/
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synergistic, additive, or antagonistic effect in the combination testing using the Loewe model36. Because 
the SerA/GlyA pair was the most likely target, we anticipated additivity as the most likely outcome.
All combinations exhibited a percent inhibition that was either similar to or lower than the calculated 
additive values in the combination studies against both strains (Fig.  3). Of note is that the SERA-126/
SIM1-074 combination against S. Typhimurium resulted in lower than expected percent inhibition by 
30–45% (Fig.  3). This effect was outside the experimental uncertainty (3–7%) of the difference of the 
measurements from the simple additive assumption, and suggests potential antagonism in this case. No 
synergy was observed.
Discussion
We present data here that evaluated how accurately systems biology-based metabolic models can predict 
SL gene pairs in four species of Enterobacteriaceae, especially E. coli and S. Typhimurium; a workflow 
for the discovery of combination inhibitors directed against SL pairs; and a set of compound pairs that 
inhibit growth of E. coli and S. Typhimurium in plate-based whole cell anti-bacterial assays in an additive 
manner, which was consistent with the predicted outcome for the presumed SL pair targeted by the com-
pounds. These results highlight specific areas in which metabolic models can be improved and evaluate 
the ability of the models to guide the selection of anti-bacterial drug combinations.
Compound
IC50 (μM) (std dev)
Possible SL TargetsbE. coli S. Typh.
SERA-126 
88 (3) 41 (4)
HemF(+ ), HemN(+ + ) 
SucC(-), LpdA(+ ) 
SerA(+ + + ), GlyA(-) 
Mdh(+ ), Ppc(-)
SIM1-074 
21% (2) 49% (3) ~155
HemF(+ ), HemN(+ + ) 
SucC(+ + + ), LpdA(-) 
SerA(+ + ), GlyA(+ ) 
Mdh(-), Ppc(-)
SIM4-003 
32 (1) 11 (0)
HemF(-), HemN(+ + ) 
SucC(+ + ), LpdA(+ ) 
SerA(+ + + ), 
GlyA(+ + ) Mdh(+ + ), 
Ppc(-)
Table 3.  IC50 data for hit compounds in bacterial growth inhibition assays, n = 2 with standard 
deviations to one significant figure in parentheses. For the weak inhibitor SIM1-074, percent inhibitions at 
the top dose, 200 μ M, are reported. One experiment provided sufficient data to calculate an IC50 (155 μ M). 
The possible SL targets for each compound were determined by docking the compounds against each of the 
eight proteins. Each “+ ” symbol is one standard deviation above the average of random compounds docked 
in the binding site. A “-” symbol implies that the compound did not dock into that site or was less than one 
standard deviation from the random compound average.
www.nature.com/scientificreports/
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The overall accuracy rate in identifying SL pairs in this study was 25% to 43%, but the true value 
is likely different due to several factors. One such factor was the manner in which putative SL pairs 
were selected for experimental testing. The selections balanced two different goals: to be amenable to 
the discovery of new inhibitors and simultaneously to provide data about the ability of the models to 
predict synthetic lethality in an a priori manner. Based on these two criteria, the pairs were filtered as 
follows. First, pairs in which one of the two genes was known to be singly essential experimentally were 
removed from the list. These pairs are clear incorrect model predictions. Second, pairs in which one 
member was a membrane-bound protein were removed because such proteins are more difficult drug 
targets than their cytoplasmic counterparts. There were ten such pairs for the E. coli EDL933 model after 
simulation in M9 medium. Third, pairs already known to be synthetically lethal were removed so that 
this study remained focused on the discovery of new SL pairs rather than revisit known ones. Nine pairs 
fit this category for the E. coli EDL933 model after simulation in M9 medium, and we ruled out seven of 
them. We constructed one pair, purT/purN, because the reported double mutant had additional genetic 
modification besides the two deletions that might have impacted synthetic lethality. We constructed a 
second pair, metE/metH, to explore the limitations of the metabolic models (see below). In the end, we 
selected from a list of 52 remaining putative SL pairs in E. coli EDL933 for experimental testing, and 
the accuracy rate calculated here was based on this subset. A similar analysis was performed for the S. 
Typhimurium model.
Several specific cases highlight the limitations of metabolic models. For example, a cofactor not 
accounted for in the models plays an essential role in the reaction catalyzed by MetE/MetH. This pair was 
predicted by the E. coli EDL933 model, as well as the iJO1366 model for the K12 MG1655 strain10, to be 
synthetically lethal in both LB and glucose M9. We tested this prediction by constructing the two single 
Figure 3. Percent growth inhibition in combination studies against (A) E. coli and (B) S. Typhimurium. 
The actual percent growth inhibitions achieved by testing two compounds in combination (blue bars) were 
compared with expected values based on simple additivity according to the Loewe model (red bars). The 
standard deviation of the single agent and combination studies ranged as high as 10% but was typically 
2–5%. The calculated expected percent growth inhibition for S. Typhimurium was greater than 100%, but 
is represented here as 100%. Asterisks (*) denote statistically significant differences (p < 0.05) between the 
actual and the expected percent growth inhibition using t-test.
www.nature.com/scientificreports/
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mutants and the double mutant, finding that all three were viable in LB. In glucose M9, however, only 
Δ metH was viable; Δ metE and the double mutant Δ metEΔ metH were both non-viable. Therefore, the 
double mutant was not a true SL pair since metE is singly essential under this condition. Both enzymes 
catalyze the same essential reaction, but MetH absolutely requires cobalamin to function37. MetH is inac-
tive in glucose M9 because cobalamin is not a component of the medium, resulting in the single essenti-
ality phenotype of metE under this condition. The metabolic models used here do not explicitly account 
for details such as cofactors, a deficiency that led to the erroneous prediction of synthetic lethality for 
this pair. The latest iterations of metabolic models, however, do account for additional features such as 
gene expression, protein synthesis, and cofactor usage, and therefore correctly predict the requirement 
for cobalamin for this pair38.
Several reasons might account for the low number of compounds identified for each SL protein 
derived from virtual screening, as only one pair of compounds targeting one SL pair was found. First, 
the docking methodology has a significant error rate even for well-explored systems, although virtual 
screening typically identifies compounds at a higher rate than random screening39. Second, there were 
two possible sites of competitive inhibition for many of the enzymes, a cofactor binding site and a sec-
ond one for the substrate. In these cases, we docked to each site in order to identify a greater number 
of possible inhibitors. The modifications to the binding sites were intended to mimic reactants, products 
or transition states in order to fashion the binding site shape appropriately. Third, there were no crystal 
structures containing an inhibitor bound to the protein for any of the eight proteins, which increases the 
difficulty of the chemical search.
In a similar fashion, there are several reasons for the lack of activity observed in the growth inhibition 
assays during testing of both individual compounds and combination testing. The hit rate after testing 
of individual compounds was ~1%. Factors such as low compound permeability, efflux, off-target bind-
ing, and poor target engagement inside the bacterial cell likely contributed to the steep drop-off in the 
number of compounds that passed from the virtual to the experimental screening steps as these factors 
are not fully taken into account during virtual screening. Moreover, the screen was performed against 
wild-type cells. In this design, compounds should not display strong activity when present individu-
ally since they would inhibit only one of the two proteins in the SL pair, making it difficult to identify 
promising agents that might be active in combination. Future studies might approach this problem by 
screening against knockout mutants rather than the wild-type variant. For example, if two proteins X and 
Y form an SL pair, one would perform virtual screening against protein X to identify potential inhibitors, 
and then perform biological screening of those inhibitors using mutants containing deletions in gene Y. 
One would do the opposite case as well. Active compounds identified in these two screens would have 
a greater chance of having the expected mechanism of action, inhibition of the target protein in the SL 
pair, rather than inhibition arising from a different or non-specific mechanism. The compounds would 
then be subjected to combination studies.
Looking forward, the findings presented here pinpoint specific ways in which metabolic models can 
be improved, and thereby provide a guide for future experimental work. In turn, models that have greater 
biological accuracy would increase their utility across many different fields, and would serve as the 
foundation of a workflow that aims to discover combination inhibitors against SL protein pairs. This task 
would be difficult to implement without the use of metabolic models as a guide due to the extremely 
large number of possible protein pairs. Consequently, the discovery of combination therapeutics might 
become much more feasible as the models are improved and refined screening strategies are adopted.
Materials and Methods
Strains and media. All knockout mutants were created in Escherichia coli EDL933 (ATCC 700927) 
or Salmonella enterica serovar Typhimurium 14028s (ATCC 14028). Both strains are enteric pathogens. 
Compound screening was performed against E. coli Seattle 1946 (ATCC 25922), which is a Clinical and 
Laboratory Standards Institute (CLSI) control strain for antimicrobial susceptibility testing, and against 
S. Typhimurium 14028s.
All strains were grown in either Luria-Bertani (LB) broth/agar or glucose M9 media. The M9 medium 
contained either 2 g/L glucose, 100 μ M CaCl2, 2 mM MgSO4, 6.8 g/L Na2HPO4, 3 g/L KH2PO4, 0.5 g/L 
NaCl, 1 g/L NH4Cl, and 250 μ L/L trace elements. The trace element solution consisted of (per liter): 
FeCl3•6H2O (16.67 g), ZnSO4•7H2O (0.18 g), CuCl2•2H2O (0.12 g), MnSO4•H2O (0.12 g), CoCl2•6H2O 
(0.18 g) and Na2EDTA•2H2O (22.25 g). Antibiotics were added as necessary at the following concentra-
tions: ampicillin at 100 μ g/mL, kanamycin at 50 μ g/mL, and chloramphenicol at 25 μ g/mL. LB powder 
was purchased from EMD Chemicals (Gibbstown, NJ) and used at the manufacturer’s recommended con-
centration. All other chemicals were purchased from Fisher Scientific (Waltham, MA) or Sigma-Aldrich 
(St. Louis, MO).
Mathematical modeling and prediction of synthetic lethal gene pairs. Metabolic network 
reconstructions for E. coli K12 MG1655 and EDL93310,25, K. pneumoniae MGH 7857826, Y. pestis CO9227, 
and S. Typhimurium LT228 were loaded into and simulated using the python version of the COBRA 
Toolbox40. These models can be downloaded from the BiGG database (bigg.ucsd.edu)41. All model reac-
tions retained their default bounds10. Both glucose M9 and BCS defined media were simulated by setting 
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a lower bound of each exchange reaction as listed in Supplementary Dataset 1. LB media was likewise 
simulated by setting bounds on each exchange reaction as indicated in Supplementary Dataset 1.
Each single knockout strain was modeled by using the delete_model_gene function to constrain each 
reaction catalyzed by the corresponding enzyme to zero. Analogously, double gene deletions were calcu-
lated using the double_gene_deletetion_fba module and double reaction deletions were performed using 
the double_reaction_deletion module. Model growth phenotypes were determined using flux balance 
analysis (FBA) with the core biomass reaction as the objective. If a particular knockout resulted in a sim-
ulated growth rate equal to zero, that gene or set of genes was deemed to be singly essential or synthet-
ically lethal, respectively. As an example, an IPython notebook with command line codes used to carry 
out this analysis for the E. coli K-12 MG1655 iJO1366 model is available at http://nbviewer.ipython.org/
github/JonM4024/synthetic_lethals/blob/master/double_deletions_example.ipynb. The Gurobi (Gurobi 
Optimizer Version 5.6, Gurobi Optimization, Inc.) linear programming solver was used to perform FBA.
Construction of gene deletion mutants in E. coli and S. Typhimurium. All gene knockouts 
were created using the protocol of Datsenko and Wanner42. Briefly, a kanamycin resistance cassette con-
taining flanking FRT sites was generated by PCR using pKD13 as the template. The ends of the cassette 
comprised 60 nucleotides that contained the start or stop codon plus 57 bp that were homologous to the 
57 bp immediately upstream and downstream of gene to be deleted. Correct insertion of the marker and 
subsequent removal from the chromosome were confirmed by PCR and Sanger sequencing. All PCR 
products were purified with the QIAGEN PCR clean-up kit (Valencia, CA).
Virtual and Compound Screening. Crystal structures of six proteins were selected from the protein 
databank (www.rcsb.org) which were identical in sequence to the proteins found in the two bacteria. 
Two homology models were developed (HemF and LpdA) because no crystal structures were available. 
In total, thirteen sites were used for docking. Preference was given to those structures that contained a 
co-crystalized substrate or inhibitor so that we could select compounds that likely bind at a catalytic site. 
Standardized methods were used to prepare each binding site for docking, and to model the sites with 
compounds that confer appropriate shape and electrostatic interactions for potential inhibitory com-
pounds. Diverse compounds from a library of 300,000 to 600,000 commercial compounds were docked 
using high throughput virtual screening (HTVS) precision. The best scoring compounds were subjected 
to atom pair similarity43 calculations to determine chemically similar structures with a similarity cutoff 
of 70–80%. In addition, compounds that contained the maximum HierS scaffolds44 of any compound 
on the HTVS list were also selected. The resulting combined list of compounds was docked again using 
standard precision. Compounds that docked well according to the Glide docking program and scored 
well based on a complementary scoring scheme were examined manually and purchased, if available.
Our selection choices were guided by the need for at least one or two single-agent inhibitors per 
protein target. Therefore, we set a goal of testing a minimum of 200 compounds per protein target based 
on reported success rates of selecting true active compounds in typical in vitro biochemical screens by 
docking methods. Docking methods provide a mean enrichment factor of 1–60 over random selections 
with an enrichment of 10 being a reasonable expectation, or approximately a 10% hit-rate45. We also 
assumed that only ~10% of compounds would permeate the Gram-negative cell walls yielding a net 1% 
hit rate in bacterial assays.
After identifying weak hits in the bacterial growth inhibition assay, we selected chemically similar 
compounds and likewise docked them to their putative binding site. The selection of similar compounds 
was done using atom pair similarity43 calculations with a similarity cutoff of 70–80%. These similar com-
pounds were then docked using the same methods as the original compounds. Any resulting compounds 
that met the same docking score criteria as the original compounds were purchased, if available.
The IC50 and percent inhibition for each purchased compound was tested in bacterial growth inhibi-
tion assays. All active compounds were re-confirmed by carefully reweighing them to measure percent 
inhibition and IC50 more precisely. Based on the percent growth inhibition data, the best concentrations 
for combination testing were chosen. A 2×2 matrix of concentrations was chosen such that the simple 
additive values would be in the 25–75% inhibition range. This choice allows synergy to be distinguished 
from the combined experimental uncertainty of each compound tested alone.
Tests were also conducted to assess compound turbidity in each of the studies to determine the inter-
ference (if any) from the test compounds that could affect the absorbance readings of the assay at 600 
nm. None of the compounds had any interference with absorbance at 600nm.
Additional details describing the virtual and compound screening procedures can be found in 
Supplementary File 1.
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